In addition to directly targeting MHC-I APP genes, EZH2 inhibition can enhance tumor immunogenicity through derepression of endogenous retroviruses, enhanced IFN signaling, and increased production of pro-inflammatory chemokines CXCL9 and CXCL10 (Canadas et al., 2018, Peng et al., 2015, Zingg et al., 2017, Wee et al., 2014). Here, CXCL9 is linked to neoplasm.